scorecardresearchNectar Lifesciences Share Price Live NSE, BSE, Today - Nectar Lifesciences
Mintgenie
Asian Paints3,300.706.85 (0.21%)
Axis Bank1,026.0011.90 (1.17%)
Bajaj Finance7,838.65-32.15 (-0.41%)
Bajaj Finserve1,566.15-1.80 (-0.11%)
Bharti Airtel919.607.45 (0.82%)
HCL Technologies1,261.550.95 (0.08%)
HDFC Bank1,527.20-10.45 (-0.68%)
Hindustan Unilever2,501.3021.65 (0.87%)
ICICI Bank943.15-5.40 (-0.57%)
ITC449.106.70 (1.51%)
Indusind Bank1,439.0015.50 (1.09%)
Infosys1,467.557.50 (0.51%)
Kotak Mahindra Bank1,765.252.60 (0.15%)
Larsen & Toubro2,961.7049.40 (1.70%)
Mahindra & Mahindra1,590.15-5.25 (-0.33%)
Maruti Suzuki India10,699.65150.05 (1.42%)
NTPC239.35-0.85 (-0.35%)
Nestle India22,905.95-96.75 (-0.42%)
Power Grid Corporation Of India199.350.95 (0.48%)
Reliance Industries2,369.1027.55 (1.18%)
State Bank Of India589.50-4.80 (-0.81%)
Sun Pharmaceutical Industries1,141.0016.25 (1.44%)
Tata Consultancy Services3,587.654.50 (0.13%)
Tata Motors620.400.65 (0.10%)
Tata Steel128.15-0.70 (-0.54%)
Tech Mahindra1,288.656.30 (0.49%)
Titan Company3,221.75-40.55 (-1.24%)
Ultratech Cement8,295.3569.00 (0.84%)
Wipro415.602.85 (0.69%)

Nectar Lifesciences

BSE: 532649 | NSE: NECLIFE | ISIN: INE023H01027 | SECTOR: Biotechnology & Drugs

₹24.88 0.03 (0.12%)

27 Sep 2023, 09:58 (IST)

  • Open

    25.35

  • High

    25.35

  • Low

    24.81

  • Prev Close

    24.85

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    5.58B

  • Volume

    49.31K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    24.96
View all metrics

Promoter Pledge Holding - 44.35%

Promoter NameNo of SharesPercentage
SANJIV GOYAL5,58,45,60031.33%
SANJIV (HUF)4,36,22,40024.47%

Company Description

  • Biotechnology & Drugs

  • BSE

    532649

  • NSE

    NECLIFE

  • ISIN

    INE023H01027

Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.

Company Officers

  • Sanjiv Goyal

    Executive Chairman of the Board, Managing Director

  • Amit Chadah

    Chief Executive Officer

  • Sushil Kapoor

    Chief Financial Officer

  • Neha Vaishnav

    Chief Compliance Officer, Company Secretary

  • Ravi Aggarwal

    Vice President - Accounts

  • Puneet Sud

    Additional Director, Wholetime Director - Operations